Serotonin, Impulsivity, and Cocaine Dependence Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00297505
Recruitment Status : Completed
First Posted : February 28, 2006
Last Update Posted : January 12, 2017
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to compare the effects of citalopram versus placebo given in the context of contingency management for cocaine dependence.

Condition or disease Intervention/treatment Phase
Cocaine Dependence Drug: citalopram Phase 2

Detailed Description:
Cocaine dependence continues to be a significant public health problem, for which there is no FDA approved pharmacotherapy. This study is a 12-week, double blind, placebo controlled trial of citalopram for cocaine dependence. The primary outcome measure is benzoylecgonine positive urines. Secondary measures of side effects and craving are also examined.

Study Type : Interventional  (Clinical Trial)
Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Serotonin, Impulsivity, and Cocaine Dependence Treatment
Study Start Date : April 2001
Study Completion Date : November 2004

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. The presence of cocaine metabolites in urine weekly.

Secondary Outcome Measures :
  1. Retention rate and cocaine cravings weekly.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male and female subjects age 18 to 50 who currently meet DSM-IV criteria for cocaine dependence.
  • female subjects: a negative pregnancy test

Exclusion Criteria:

  • current or past DSM-IV Axis I disorder other than substance abuse/dependence
  • any serious non-psychiatric medical illness requiring ongoing medical treatment
  • substance dependence other than cocaine within the last 3 months
  • negative urine drug screen for cocaine at time of testing
  • for female subjects: a positive pregnancy test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00297505

United States, Texas
University of Texas - Houston Health Science Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Frederick G Moeller, M.D. The University of Texas Health Science Center, Houston

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00297505     History of Changes
Other Study ID Numbers: R01DA008425 ( U.S. NIH Grant/Contract )
First Posted: February 28, 2006    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: February 2006

Keywords provided by National Institute on Drug Abuse (NIDA):
Cocaine; citalopram; impulsivity; serotonin

Additional relevant MeSH terms:
Cocaine-Related Disorders
Impulsive Behavior
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Serotonin Receptor Agonists
Serotonin Agents
Serotonin Uptake Inhibitors
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents